Big news in medical weight loss: in December 2025, the FDA approved the first once-daily oral GLP-1 medication for chronic weight management and cardiovascular risk reduction. This new option, an oral form of Wegovy® (semaglutide), offers patients a powerful alternative to weekly injections, though as with any medication, there are pros and cons to every medication.
At Nervana Medical, we’re excited about what this means for patients who want effective, evidence-based weight loss without injections, but we want to ensure you are equipped with accurate information and encourage a thorough discussion with your provider to determine what medication AND route is best for YOU!
What Is the Wegovy® Pill?
The Wegovy pill is a once-daily oral version of semaglutide, the same medication used in injectable Wegovy and Ozempic. It works by:
- Reducing appetite
- Increasing feelings of fullness
- Slowing digestion
- Improving blood sugar regulation
This helps patients eat less naturally and lose weight in a sustainable way.
The pill was approved for adults with:
- Obesity, or
- Overweight plus at least one weight-related condition, such as high blood pressure, cholesterol issues, or insulin resistance
It also carries benefits for heart health, reducing cardiovascular risk in appropriate patients.
How Effective Is the Wegovy Pill?
In a large clinical trial following patients for over a year:
- Patients lost an average of 15–16% of their body weight
- Even without strict dieting, weight loss averaged around 14%
- This was far greater than placebo, where weight loss was minimal
To put this into perspective: for someone weighing 200 pounds, that could mean 30+ pounds of weight loss.
These results are very similar to the injectable version of Wegovy, making the pill a truly effective alternative. * Please note that strict compliance adherence does affect overall results.
Is the Pill as Safe as the Injections?
Yes. The safety profile of the oral Wegovy pill is very similar to injectable semaglutide.
The most common side effects include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
These symptoms are usually:
- Mild to moderate
- Temporary
- Most noticeable during dose increases
At Nervana Medical, we carefully guide dosing and provide support to help minimize side effects and improve long-term success.
How Is the Wegovy Pill Taken?
This is where the pill differs most from injections.
The Wegovy pill:
- Is taken once daily
- Must be taken on an empty stomach
- Requires waiting 30 minutes before eating, drinking anything besides water, or taking other medications
- Higher dosing is required given the differences in bioavailability from oral vs injectables
While this routine works well for many patients, it does require consistency. Weekly injections are more flexible, so choosing the right option depends on your lifestyle and preferences.
Why This Is a Game-Changer for Weight Loss Patients
Until now, effective GLP-1 weight loss treatment mostly required injections. The Wegovy pill:
- Removes needle anxiety
For some patients, this convenience improves long-term adherence and results.
Pill vs Injection: Which Is Better?
There is no single “best” option only the best option for you. Real-world data demonstrate that injectable semaglutide shows superior persistence and slightly greater weight loss compared to oral formulations, though both achieve clinically meaningful improvements in glycemic control and body weight
Injectable Wegovy may be better if:
- You want maximum weight loss
- You prefer weekly dosing
- You don’t want fasting requirements (The strict administration requirements for oral semaglutide; fasting state with ≤120 mL water, 30-minute wait before food or other medications; likely contribute to lower persistence. These practical barriers may be particularly challenging for patients with complex medication regimens or irregular schedules.)
- Have compliance issues where once a week dosing is preferred over daily dosing
Oral Wegovy may be better if:
- You strongly prefer a pill over injections
- You’re consistent with morning routines
Both options are effective and safe when prescribed appropriately.
- Cardiovascular: No direct head-to-head trials have compared cardiovascular outcomes between oral and injectable semaglutide formulations, but recent meta-analyses and individual cardiovascular outcomes trials demonstrate that both formulations reduce major adverse cardiovascular events (MACE) by similar magnitudes in type 2 diabetes, with comparable benefits extending to broader metabolic parameters including diabetes remission rates.
- Weight Loss: Oral semaglutide 25 mg daily produces comparable weight loss to injectable semaglutide 2.4 mg weekly. In the OASIS 4 trial, oral semaglutide 25 mg resulted in 13.6% mean weight reduction over 68 weeks (11.4 percentage points more than placebo).[2] This is similar to the STEP 1 trial results with injectable semaglutide 2.4 mg weekly, which achieved 14.9% weight reduction (12.4 percentage points more than placebo).[2][3] The higher investigational dose of oral semaglutide (50 mg daily) achieved 15.1% weight reduction in OASIS 1, nearly identical to injectable formulations.[4][5]
- Diabetes Remission and Metabolic Benefits: Both formulations produce substantial improvements in diabetes remission rates. In the OASIS 1 trial, oral semaglutide 50 mg resulted in a greater proportion of participants with baseline prediabetes reverting to normoglycemia compared to placebo.[4] Injectable semaglutide 2.4 mg has shown similar benefits in reversing prediabetes and improving insulin sensitivity.[4]
Beyond glycemic control, both formulations improve multiple cardiometabolic parameters:
- Lipid profiles: Reductions in VLDL cholesterol, free fatty acids, and triglycerides, with increases in HDL cholesterol[4]
- Blood pressure: Significant reductions leading to decreased need for antihypertensive medications[4]
- Insulin sensitivity: Reductions in both fasting plasma glucose and serum insulin concentrations[4]
- Systemic inflammation: 57.3% reduction in high-sensitivity C-reactive protein with oral semaglutide 50 mg, shifting patients from high to intermediate cardiovascular risk categories[4]
- Hepatic steatosis: Women treated with subcutaneous semaglutide showed significantly greater reductions in hepatic steatosis index and liver transaminases compared to oral formulation[5]
- HbA1c: Real-world data confirm that improvements in HbA1c and body weight are similar between formulations when used in matched populations, though injectable semaglutide may produce slightly greater weight loss and better treatment persistence.[6][7]
Sex-specific differences may also influence outcomes. Women treated with subcutaneous semaglutide showed significantly greater reductions in hepatic steatosis index and liver transaminases compared to oral formulation, while men experienced greater reductions in weight, HbA1c, and LDL cholesterol with injectable versus oral semaglutide.[6]
Cost and Availability
The oral Wegovy pill is expected to launch in the U.S. in January 2026.
- A starter dose is expected to be available through pharmacies
- Cash-pay pricing is anticipated around $149 per month for early dosing (1.5 mg-4 mg) and $299 for 9-25 mg.
- Injectable pricing may actually be cheaper in some scenarios
Our team stays current on options and helping patients navigate affordability whenever possible.
Personalized Weight Loss at Nervana Medical
Weight loss is not one-size-fits-all. At Nervana Medical in Sandy, Utah, we:
- Review your medical history and goals
- Help you choose between oral or injectable options
- Monitor labs, side effects, and progress
- Combine medication with nutrition and lifestyle guidance
- Explore additional options when patients become stagnant
Whether you’re new to medical weight loss or looking for an alternative to injections, we’re here to help you choose the safest and most effective path forward.
Ready to Learn More?
If you live in Sandy, Salt Lake City, or surrounding areas, schedule a consultation with our team to see whether the new Wegovy pill or another option is right for you.
Medical weight loss should feel supported, personalized, and sustainable.
*Oral options will be available to our medical concierge patients should patient/provider treatment plan determine that oral option is the best route for you!
References
Aroda, V. R., Erhan, U., Jelnes, P., Meier, J. J., Nauck, M. A., & Zinman, B. (2023). Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, Obesity & Metabolism, 25(5), 1385–1397. https://doi.org/10.1111/dom.14990
Apovian, C. M., Aronne, L. J., & Barenbaum, S. R. (2025). Clinical management of obesity (3rd ed.). The Obesity Society.
Bonora, B. M., Russo, G., Leonetti, F., et al. (2024). Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: A multicenter real-world study. Journal of Endocrinological Investigation, 47(6), 1395–1403. https://doi.org/10.1007/s40618-024-02309-2
Fadini, G. P., Bonora, B. M., Ghiani, M., et al. (2024). Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts. Diabetes, Obesity & Metabolism, 26(6), 2390–2400. https://doi.org/10.1111/dom.15554
Ferrara, F., Bazzani, D., & Crivelli, B. (2025). Progress and challenges in obesity pharmacotherapy: Semaglutide as a milestone. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04319-0
Formichi, C., Baronti, W., de Gennaro, G., et al. (2024). Real-world use of oral versus subcutaneous semaglutide in patients with type 2 diabetes: Which option for which patient? Journal of Endocrinological Investigation, 47(11), 2679–2690. https://doi.org/10.1007/s40618-024-02369-4
Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg once daily in adults with overweight or obesity (OASIS 1): A randomized, double-blind, placebo-controlled phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6
Lee, M. M. Y., Sattar, N., Pop-Busui, R., et al. (2025). Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral GLP-1 receptor agonists in type 2 diabetes: A systematic review and meta-analysis. Diabetes Care, 48(5), 846–859. https://doi.org/10.2337/dc25-0241
Marx, N., Deanfield, J. E., Mann, J. F. E., et al. (2025). Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes according to SGLT2 inhibitor use: Prespecified analyses of the SOUL randomized trial. Circulation, 151(23), 1639–1650. https://doi.org/10.1161/CIRCULATIONAHA.125.074545
McGuire, D. K., Marx, N., Mulvagh, S. L., et al. (2025). Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. The New England Journal of Medicine, 392(20), 2001–2012. https://doi.org/10.1056/NEJMoa2501006
Mayer, C. S., & Fontelo, P. (2024). Semaglutide use in people with obesity and type 2 diabetes: Real-world data from the All of Us Research Program. Diabetes, Obesity & Metabolism, 26(11), 4989–4995. https://doi.org/10.1111/dom.15911
Novo Nordisk. (2025). Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration. https://www.fda.gov
Piccione, A., Bonsangue, M., Barone, M., et al. (2025). Sex-specific responses to oral versus subcutaneous semaglutide in type 2 diabetes: A 12-month real-world study. Nutrition, Metabolism & Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2025.104462
Samuels, J. M., Ye, F., Irlmeier, R., et al. (2025). Real-world titration, persistence, and weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, Obesity & Metabolism. https://doi.org/10.1111/dom.70004
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. The New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/NEJMoa2500969
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183